By Business/Source
Currency:EUR
2026/Q1
Stock NameRevenueRatio
Biopharmaceutical and Diagnostic Solutions249.2M91.08%
Engineering55.6M20.32%
Adjustments, eliminations and unallocated items-31.2M-11.40%
By Country/Region
Currency:EUR
2025/FY
Stock NameRevenueRatio
EMEA690.34M58.19%
North America362.06M30.52%
APAC101.48M8.55%
South America32.4M2.73%